ZP3 and invasive breast carcinoma: For patients with prostate adenocarcinoma (PRAD), triple-negative breast cancer (BRCA-TNBC) and lung squamous cell carcinoma (LUSC), at least 50% of tumors display medium to high ZP3-Cancer expression levels.